Surgical Outcomes and Comparative Analysis of Transduodenal Ampullectomy and Pancreaticoduodenectomy: A Single-Center Study.


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 15 04 2021
accepted: 26 11 2021
pubmed: 22 12 2021
medline: 24 3 2022
entrez: 21 12 2021
Statut: ppublish

Résumé

Transduodenal ampullectomy (TDA) is performed for adenoma or early cancer of the ampulla of Vater (AoV). This study aimed to analyze the short- and long-term outcomes of TDA (TDA group) when compared with conventional pancreaticoduodenectomy (PD) or pylorus-preserving pancreaticoduodenectomy (PD group). Patients who underwent TDA between January 2006 and December 2019, and PD cases performed for AoV malignancy with carcinoma in-situ (Tis) (high-grade dysplasia, HGD) and T1 and T2 stage from January 2010 to December 2019 were reviewed. Forty-six patients underwent TDA; 21 had a benign tumor, and 25 cases with malignant tumors were compared with PD cases (n = 133). Operation time (p < 0.001), estimated blood loss (p < 0.001), length of hospital stays (p = 0.003), and overall complication rate (p < 0.001) were lower in the TDA group than in the PD group. Lymph node metastasis rates were 14.6% in pT1 and 28.9% in pT2 patients. The 5-year disease-free survival and 5-year overall survival rates for HGD/Tis and T1 tumor between the two groups were similar (TDA group vs PD group, 72.2% vs 77.7%, p = 0.550; 85.6% vs 79.2%, p = 0.816, respectively). TDA accompanied with lymph node dissection is advisable in HGD/Tis and T1 AoV cancers in view of superior perioperative outcomes and similar long-term survival rates compared with PD.

Sections du résumé

BACKGROUND BACKGROUND
Transduodenal ampullectomy (TDA) is performed for adenoma or early cancer of the ampulla of Vater (AoV). This study aimed to analyze the short- and long-term outcomes of TDA (TDA group) when compared with conventional pancreaticoduodenectomy (PD) or pylorus-preserving pancreaticoduodenectomy (PD group).
METHODS METHODS
Patients who underwent TDA between January 2006 and December 2019, and PD cases performed for AoV malignancy with carcinoma in-situ (Tis) (high-grade dysplasia, HGD) and T1 and T2 stage from January 2010 to December 2019 were reviewed.
RESULTS RESULTS
Forty-six patients underwent TDA; 21 had a benign tumor, and 25 cases with malignant tumors were compared with PD cases (n = 133). Operation time (p < 0.001), estimated blood loss (p < 0.001), length of hospital stays (p = 0.003), and overall complication rate (p < 0.001) were lower in the TDA group than in the PD group. Lymph node metastasis rates were 14.6% in pT1 and 28.9% in pT2 patients. The 5-year disease-free survival and 5-year overall survival rates for HGD/Tis and T1 tumor between the two groups were similar (TDA group vs PD group, 72.2% vs 77.7%, p = 0.550; 85.6% vs 79.2%, p = 0.816, respectively).
CONCLUSION CONCLUSIONS
TDA accompanied with lymph node dissection is advisable in HGD/Tis and T1 AoV cancers in view of superior perioperative outcomes and similar long-term survival rates compared with PD.

Identifiants

pubmed: 34931288
doi: 10.1245/s10434-021-11190-9
pii: 10.1245/s10434-021-11190-9
pmc: PMC8933369
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2429-2440

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : ErratumIn

Informations de copyright

© 2021. The Author(s).

Références

Albores-Saavedra J, Schwartz AM, Batich K, Henson DE. Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol. 2009;100:598–605.
doi: 10.1002/jso.21374
Talamini MA, Moesinger RC, Pitt HA, et al. Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg. 1997;225:590–9 (discussion 599-600).
doi: 10.1097/00000658-199705000-00015
Gouma DJ, van Geenen RC, van Gulik TM, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg. 2000;232:786–95.
doi: 10.1097/00000658-200012000-00007
Moekotte AL, Lof S, Van Roessel S, et al. Histopathologic predictors of survival and recurrence in resected ampullary adenocarcinoma: international multicenter cohort study. Ann Surg. 2019. https://doi.org/10.1097/sla.0000000000003177 .
doi: 10.1097/sla.0000000000003177
Park JS, Yoon DS, Kim KS, et al. Factors influencing recurrence after curative resection for ampulla of Vater carcinoma. J Surg Oncol. 2007;95:286–90.
doi: 10.1002/jso.20665
Sierzega M, Nowak K, Kulig J, Matyja A, Nowak W, Popiela T. Lymph node involvement in ampullary cancer: the importance of the number, ratio, and location of metastatic nodes. J Surg Oncol. 2009;100:19–24.
doi: 10.1002/jso.21283
Yoon YS, Kim SW, Park SJ, et al. Clinicopathologic analysis of early ampullary cancers with a focus on the feasibility of ampullectomy. Ann Surg. 2005;242:92–100.
doi: 10.1097/01.sla.0000167853.04171.bb
Aiura K, Hibi T, Fujisaki H, et al. Proposed indications for limited resection of early ampulla of Vater carcinoma: clinico-histopathological criteria to confirm cure. J Hepatobiliary Pancreat Sci. 2012;19:707–16.
doi: 10.1007/s00534-011-0492-4
Winter JM, Cameron JL, Olino K, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg. 2010;14:379–87.
doi: 10.1007/s11605-009-1080-7
Kayahara M, Nagakawa T, Ohta T, Kitagawa H, Miyazaki I. Surgical strategy for carcinoma of the papilla of Vater on the basis of lymphatic spread and mode of recurrence. Surgery. 1997;121:611–7.
doi: 10.1016/S0039-6060(97)90048-9
Kim H, Kwon W, Kim JR, Byun Y, Jang JY, Kim SW. Recurrence patterns after pancreaticoduodenectomy for ampullary cancer. J Hepatobiliary Pancreat Sci. 2019;26:179–86.
doi: 10.1002/jhbp.618
Beger HG, Treitschke F, Gansauge F, Harada N, Hiki N, Mattfeldt T. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg. 1999;134:526–32.
doi: 10.1001/archsurg.134.5.526
Amini A, Miura JT, Jayakrishnan TT, et al. Is local resection adequate for T1 stage ampullary cancer? HPB (Oxford). 2015;17:66–71.
doi: 10.1111/hpb.12297
Gao Y, Zhu Y, Huang X, Wang H, Huang X, Yuan Z. Transduodenal ampullectomy provides a less invasive technique to cure early ampullary cancer. BMC Surg. 2016;16:36.
doi: 10.1186/s12893-016-0156-z
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
doi: 10.1097/01.sla.0000133083.54934.ae
Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584–91.
doi: 10.1016/j.surg.2016.11.014
Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142:761–8.
doi: 10.1016/j.surg.2007.05.005
Ceppa EP, Burbridge RA, Rialon KL, et al. Endoscopic versus surgical ampullectomy: an algorithm to treat disease of the ampulla of Vater. Ann Surg. 2013;257:315–22.
doi: 10.1097/SLA.0b013e318269d010
Laleman W, Verreth A, Topal B, et al. Endoscopic resection of ampullary lesions: a single-center 8-year retrospective cohort study of 91 patients with long-term follow-up. Surg Endosc. 2013;27:3865–76.
doi: 10.1007/s00464-013-2996-2
Lee R, Huelsen A, Gupta S, Hourigan LF. Endoscopic ampullectomy for non-invasive ampullary lesions: a single-center 10-year retrospective cohort study. Surg Endosc. 2021;35:684–92.
doi: 10.1007/s00464-020-07433-7
Lee H, Park JY, Kwon W, Heo JS, Choi DW, Choi SH. Transduodenal ampullectomy for the treatment of early-stage ampulla of vater cancer. World J Surg. 2016;40:967–73.
doi: 10.1007/s00268-015-3316-x
Stolte M, Pscherer C. Adenoma-carcinoma sequence in the papilla of Vater. Scand J Gastroenterol. 1996;31:376–82.
doi: 10.3109/00365529609006414
Demetriades H, Zacharakis E, Kirou I, et al. Local excision as a treatment for tumors of ampulla of Vater. World J Surg Oncol. 2006;4:14.
doi: 10.1186/1477-7819-4-14
Song J, Liu H, Li Z, Yang C, Sun Y, Wang C. Long-term prognosis of surgical treatment for early ampullary cancers and implications for local ampullectomy. BMC Surg. 2015;15:32.
doi: 10.1186/s12893-015-0019-z
Askew J, Connor S. Review of the investigation and surgical management of resectable ampullary adenocarcinoma. HPB (Oxford). 2013;15:829–38.
doi: 10.1111/hpb.12038
Kawabata Y, Ishikawa N, Moriyama I, Tajima Y. What is an adequate surgical management for pTis and pT1 early ampullary carcinoma? Hepatogastroenterology. 2014;61:12–7.
pubmed: 24895785
Irani S, Arai A, Ayub K, et al. Papillectomy for ampullary neoplasm: results of a single referral center over a 10-year period. Gastrointest Endosc. 2009;70:923–32.
doi: 10.1016/j.gie.2009.04.015
Ito K, Fujita N, Noda Y, et al. Preoperative evaluation of ampullary neoplasm with EUS and transpapillary intraductal US: a prospective and histopathologically controlled study. Gastrointest Endosc. 2007;66:740–7.
doi: 10.1016/j.gie.2007.03.1081
Duffy JP, Hines OJ, Liu JH, et al. Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg. 2003;138:941–8 (discussion 948-950).
doi: 10.1001/archsurg.138.9.941
Sudo T, Murakami Y, Uemura K, et al. Prognostic impact of perineural invasion following pancreatoduodenectomy with lymphadenectomy for ampullary carcinoma. Dig Dis Sci. 2008;53:2281–6.
doi: 10.1007/s10620-007-0117-6
Lazaryan A, Kalmadi S, Almhanna K, Pelley R, Kim R. Predictors of clinical outcomes of resected ampullary adenocarcinoma: a single-institution experience. Eur J Surg Oncol. 2011;37:791–7.
doi: 10.1016/j.ejso.2011.06.008
Zhong J, Palta M, Willett CG, et al. Patterns of failure for stage I ampulla of Vater adenocarcinoma: a single institutional experience. J Gastrointest Oncol. 2014;5:421–7.
pubmed: 25436120 pmcid: 4226834

Auteurs

Eun-Ki Min (EK)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, 03722, South Korea.

Seung Soo Hong (SS)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, 03722, South Korea.

Ji Su Kim (JS)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, 03722, South Korea.

Munseok Choi (M)

Department of Surgery, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

Hyeo Seong Hwang (HS)

Department of Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, South Korea.

Chang Moo Kang (CM)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, 03722, South Korea.

Woo Jung Lee (WJ)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, 03722, South Korea.

Dong Sup Yoon (DS)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, 03722, South Korea.

Ho Kyoung Hwang (HK)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, 03722, South Korea. drhhk@yuhs.ac.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH